Navigation Links
Novel mechanisms controlling insulin release and fat deposition discovered
Date:5/13/2008

[PRESS RELEASE, 13 May 200] Scientists at the Swedish medical university Karolinska Institutet have in two recent studies shown that a receptor called ALK7 plays important roles in the regulation of body fat deposition as well as the release of insulin from beta-cells in the pancreas. These findings have implications for the development of treatments against diabetes and obesity.

We have shown in animal studies that removing the ALK7 receptor improves insulin release by beta-cells in the pancreas, and at the same time decreases fat deposition in situations of high caloric intake, says Professor Carlos Ibez, who lead the two studies that are now published as back-to-back papers in the PNAS. The well-known connections between diabetes and obesity make our combined findings quite exciting.

Up to 6 per cent of the world population is estimated to suffer from some form of diabetes, either due to a reduced ability to produce insulin, or to insulin resistance. Insulin is a hormone required by cells in the body to absorb glucose from the blood, thereby providing them with energy. Obesity has been shown to increase the risk of developing diabetes, and as overweight becomes more prevalent in the human population, so do the cases of diabetes.

The research group led by Carlos Ibez studies how signaling by growth factors and their receptors regulate different physiological functions in the body. They have recently investigated the functions of one of these receptors, called ALK7, using mutant mice (knock-out mice) lacking this receptor. They found that in the absence of ALK7, mice developed abnormally high levels of insulin in the blood, which with age led to insulin resistance and liver steatosis, a pathological condition in which the liver enlarges and accumulates abnormally high levels of fat.

In collaboration with another research group at Karolinska Institutet, led by Professor Per-Olof Berggren, they also found that Calcium signaling in pancreatic beta-cells was reduced by the actions of the growth factor Activin B through the ALK7 receptor, and that blood glucose levels regulates the expression of both Activin B and ALK7. In agreement with these results, mice lacking Activin B also developed hyperinsulinemia to a similar extent as ALK7 mutants.

In other words, our data revealed an unexpected negative feedback loop in the control of glucose-dependent insulin release, mediated the actions of Activin B on the ALK7 receptor, says Carlos Ibez.

In the second study, the scientists found that mice lacking ALK7 accumulated less fat and gained less weight than their normal counterparts when fed on a high-fat diet. They discovered that another growth factor called GDF3 could also signal via the ALK7 receptor, and that mice lacking GDF3 showed similar defects in fat deposition and weight gain as the ALK7 mutants. Intriguingly, however, mutant mice consumed equal amounts of food as their normal counterparts during the experiment.

These results show that lack of ALK7 or GDF3 improves energy balance in the body under regimes of high caloric intake, says Carlos Ibez.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
2. Discovery of a novel mechanism for the development of colon cancer
3. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
4. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
5. Scientists identify novel way to prevent cardiac fibrosis
6. Registry unveils real-world data on novel excel stent
7. Researchers sharpen search for new marine medicines with novel techniques
8. Increased hepcidin expression: A novel oncogenic signalling mechanism
9. Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
10. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... ... 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s ... the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners ... their continued efforts to provide innovative offerings to their healthcare partners. These solutions ... build dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent ...
(Date:7/26/2017)... ... ... time to sign up for the new One-A-Month Essential Oil Club for fun and ... Naturals and author of numerous books on essential oils. , , ... , Two items are included in the December mailing. , A ...
(Date:7/26/2017)... Michigan (PRWEB) , ... July 26, 2017 , ... ... appointed Medical Director for the treatment program located in Royal Oak, Michigan. ... of investors who are focused on providing the highest standards in the field of ...
(Date:7/26/2017)... ... 2017 , ... The number of adults 65 years or older is expected ... asthma control in the population are not well described. In a study published in ... journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... 2017 operating results on Monday, August 7, 2017 after ... 5:00 p.m. ET. ... broadcast of the conference call by dialing 877-201-0168 or ... approximately 15 minutes prior to the call. A live ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/21/2017)... , July 21, 2017 Did you know that ... in 2016? Or that combined spending on brand medicines, generics and ... spending, with brands accounting for just half of this (7 percent)? ... two thirds of the world,s venture capital investments in high-growth biopharmaceutical ... ...
Breaking Medicine Technology: